Healthy Living

Capricor's Cell Therapy Trial Shows Promising Results for Muscular Dystrophy

The potential for this type of cell therapy

CDC patient in earlier studies on the heart has already demonstrated the reduction of scar mass in post-MI patients. Further studies were done by using the CDC cells from the donor, to prove that they would be actual results and would not be rejected by the immune system of the person treated. Proving that rejection on the usage of donor cells (allogeneic cell therapy) did not occur, opened the possibilities of multiplying the CDC cells in laboratories and later using in any patient as per the requirement.